Literature DB >> 23561592

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis.

Shigeaki Suzuki1, Tetsuya Nishimoto, Mitsutomo Kohno, Kimiaki Utsugisawa, Yuriko Nagane, Masataka Kuwana, Norihiro Suzuki.   

Abstract

There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23561592     DOI: 10.1016/j.jneuroim.2013.03.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Slug overexpression is associated with poor prognosis in thymoma patients.

Authors:  Tianqiang Zhang; X U Chen; Xiumei Chu; Y I Shen; Wenjie Jiao; Yucheng Wei; Tong Qiu; Guanzhong Yan; Xiaofei Wang; Linhao Xu
Journal:  Oncol Lett       Date:  2015-10-30       Impact factor: 2.967

2.  Clinical predictors for the prognosis of myasthenia gravis.

Authors:  Lili Wang; Yun Zhang; Maolin He
Journal:  BMC Neurol       Date:  2017-04-19       Impact factor: 2.474

Review 3.  Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies.

Authors:  Hans Frykman; Pankaj Kumar; Joel Oger
Journal:  Front Neurol       Date:  2020-12-09       Impact factor: 4.003

4.  Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.

Authors:  Hiroyuki Murai; Shigeaki Suzuki; Miki Hasebe; Yuji Fukamizu; Ema Rodrigues; Kimiaki Utsugisawa
Journal:  Ther Adv Neurol Disord       Date:  2021-03-16       Impact factor: 6.570

5.  Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.

Authors:  Munenori Oyama; Kensuke Okada; Masayuki Masuda; Yuko Shimizu; Kazumasa Yokoyama; Akiyuki Uzawa; Naoki Kawaguchi; Ryotaro Ikeguchi; Yasunobu Hoshino; Taku Hatano; Yukiko Ozawa; Jin Nakahara; Hitoshi Aizawa; Kazuo Kitagawa; Nobutaka Hattori; Satoshi Kuwabara; Hiroyuki Murai; Shigeaki Suzuki
Journal:  Ther Adv Neurol Disord       Date:  2020-03-18       Impact factor: 6.570

6.  Lower number of plasma exchange sessions and glomerular filtration rate decline are associated with second relapses in patients with myasthenia gravis.

Authors:  Vedran Premuzic; Ervina Bilic; Branimir Ivan Sepec; Mirea Hancevic; Hrvoje Bilic; Barbara Sitas; Rujana Sprljan Alfirev; Bojan Jelakovic
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.